American Heart Journal
Volume 163, Issue 1 , Pages 7-12 , January 2012

Design of the Trial to Assess Chelation Therapy (TACT)

  • Gervasio A. Lamas, MD

      Affiliations

    • Mount Sinai Medical Center, Miami Beach, FL
    • Corresponding Author InformationReprint requests: Gervasio A. Lamas, MD, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140.
    • ,
  • Christine Goertz, DC, PhD

      Affiliations

    • The Palmer Center for Chiropractic Research, Davenport, IA
    • ,
  • Robin Boineau, MD, MA

      Affiliations

    • The National Heart, Lung, and Blood Institute, Bethesda, MD
    • ,
  • Daniel B. Mark, MD, MPH

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Theodore Rozema, MD

      Affiliations

    • Biogenesis Medical Center, Landrum, SC
    • ,
  • Richard L. Nahin, PhD, MPH

      Affiliations

    • The National Center for Complementary and Alternative Medicine, Bethesda, MD
    • ,
  • Jeanne A. Drisko, MD

      Affiliations

    • Integrative Medicine, The University of Kansas Medical Center, Kansas City, KS
    • ,
  • Kerry L. Lee, PhD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC

Received 14 December 2010 ,Accepted 4 October 2011.

References 

  1. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and pattern of use. N Engl J Med. 1993;328:246–252
  2. Barnes PM, Powell-Griner E, McFann K, et al. Complementary and alternative medicine use among adults: United States 2002. Adv Data. 2004;343:1–19
  3. Barnes PM, Bloom B, Nahin R. Complementary and alternative medicine use among adults and children: United States, 2007⁎. National Health Statistics Reports; no 12. National Center for Health Statistics. 2008;12:1–24
  4. U.S. Department of Health and Human Services. Food and Drug Administration . Public health advisory: Edetate disodium (marketed as Endrate and generic products). [Updated: 08/09/2010;cited 2010 Nov 16]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051138.htm
  5. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988;27:41–49
  6. Ernst E. Chelation therapy for coronary heart disease: an overview of all clinical investigations. Am Heart J. 2000;140:139–141
  7. Green DJ, O’Driscoll JG, Maiorana A, et al. Effects of chelation with EDTA and vitamin B therapy on nitric oxide–related endothelial vasodilator function. Clin Exp Pharmacol Physiol. 1999;26:853–856
  8. Bolick LE, Blakenhorn DH. A quantitative study of coronary artery calcification. Am J Path. 1961;39:511
  9. U.S. Centers for Disease Control. Morbidity and Mortality Weekly Report(MMWR). Deaths associated with hypocalcemia from chelation therapy—Texas, Pennsylvania, and Oregon, 2003—2005. 2006; 55(08):204–207 [Updated: 3/2/2006; cited 2010 Nov 16]. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5508a3.htm.
  10. Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother. 1993;27:1504–1509
  11. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication—a double-blind, placebo-controlled study. J Intern Med. 1992;231:261–267
  12. Van Rij AM, Solomon C, Packer SG, et al. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation. 1994;90:1194–1199
  13. Knudtson ML, Wyse DG, Galbraith PD, et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. J Am Med Assoc. 2002;287:481–486
  14. Rozema TC. Special issue: protocols for chelation therapy. J Adv Med. 1997;10:5–90
  15. Lamas GA, Ackermann A, Hollar D, et al. Chelation therapy for patient with coronary heart disease: findings from the Pilot to Assess Chelation Therapy. J Am Coll Cardiol. 2004;252A:43
  16. Holland JF, Danielson E, Sahagian-Edwards A. Use of ethylene diamine tetra acetic acid in hypercalcemic patients. Proc Soc Exper Biol Med. 1953;84:359–364
  17. Foreman H, Finnegan C, Lushbaugh CC. Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy. JAMA. 1956;160:1042–1046
  18. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey: Manual & Interpretation Guide. Boston: Nimrod Press; 1993;
  19. Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol. 1989;64:651–654
  20. National Center for Health Statistics . Health, United Sates, 1991. Hyattsville, MD: Public Health Service; 1992;
  21. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25:333–341
  22. EuroQol Group. A new facility for the measurement of health related quality of life. Health Policy. 1990;16:199–208
  23. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events. J Am Med Assoc. 2003;290:1459–1466
  24. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed.. New York: John Wiley & Sons, Inc; 2002;
  25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn. 1958;53:457–481
  26. Cox DR. Regression models and life-tables (with discussion). J Royal Statist Soc B. 1972;34:187–220
  27. O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556
  28. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika. 1983;70:659–663
  29. Nahin RL, Barnes PM, Stussman BJ, et al. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report. 2009;1–14
  30. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–1592
  31. Miller ER, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46
  32. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017–2023

 RCT no.: NCT00044213.

 W. Douglas Weaver, MD served as guest editor for this article.

PII: S0002-8703(11)00715-0

doi: 10.1016/j.ahj.2011.10.002

American Heart Journal
Volume 163, Issue 1 , Pages 7-12 , January 2012

Article Tools